SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-089945
Filing Date
2024-08-02
Accepted
2024-08-02 16:05:28
Documents
69
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q dawn-20240630.htm   iXBRL 10-Q 2445582
2 EX-10.1 dawn-ex10_1.htm EX-10.1 368076
3 EX-10.2 dawn-ex10_2.htm EX-10.2 817793
4 EX-31.1 dawn-ex31_1.htm EX-31.1 13556
5 EX-31.2 dawn-ex31_2.htm EX-31.2 13378
6 EX-32.1 dawn-ex32_1.htm EX-32.1 7704
7 EX-32.2 dawn-ex32_2.htm EX-32.2 8605
8 GRAPHIC img13566332_0.jpg GRAPHIC 300618
9 GRAPHIC img192232465_0.jpg GRAPHIC 9664
  Complete submission text file 0000950170-24-089945.txt   10861671

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT dawn-20240630.xsd EX-101.SCH 1513321
71 EXTRACTED XBRL INSTANCE DOCUMENT dawn-20240630_htm.xml XML 1303676
Mailing Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005 650 484-0899
Day One Biopharmaceuticals, Inc. (Filer) CIK: 0001845337 (see all company filings)

IRS No.: 832415215 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40431 | Film No.: 241170937
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)